- Home
- CELU vs ABVC Comparison
CELU vs ABVC Comparison
Compare CELU & ABVC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CELU
- ABVC
- Stock Information
- Founded
- CELU 2016
- ABVC 2015
- Country
- CELU United States
- ABVC United States
- Employees
- CELU N/A
- ABVC N/A
- Industry
- CELU Biotechnology: Pharmaceutical Preparations
- ABVC Biotechnology: Pharmaceutical Preparations
- Sector
- CELU Health Care
- ABVC Health Care
- Exchange
- CELU Nasdaq
- ABVC Nasdaq
- Market Cap
- CELU 56.9M
- ABVC 52.1M
- IPO Year
- CELU N/A
- ABVC N/A
- Fundamental
- Price
- CELU $1.74
- ABVC $2.85
- Analyst Decision
- CELU Strong Buy
- ABVC
- Analyst Count
- CELU 1
- ABVC 0
- Target Price
- CELU $6.00
- ABVC N/A
- AVG Volume (30 Days)
- CELU 153.9K
- ABVC 88.0K
- Earning Date
- CELU 12-05-2025
- ABVC 11-03-2025
- Dividend Yield
- CELU N/A
- ABVC N/A
- EPS Growth
- CELU N/A
- ABVC N/A
- EPS
- CELU N/A
- ABVC N/A
- Revenue
- CELU $44,590,000.00
- ABVC $797,916.00
- Revenue This Year
- CELU N/A
- ABVC $735.18
- Revenue Next Year
- CELU $76.00
- ABVC N/A
- P/E Ratio
- CELU N/A
- ABVC N/A
- Revenue Growth
- CELU 4.45
- ABVC 56.52
- 52 Week Low
- CELU $1.00
- ABVC $0.40
- 52 Week High
- CELU $5.22
- ABVC $5.48
- Technical
- Relative Strength Index (RSI)
- CELU 34.57
- ABVC 46.89
- Support Level
- CELU $1.62
- ABVC $2.75
- Resistance Level
- CELU $1.99
- ABVC $3.03
- Average True Range (ATR)
- CELU 0.11
- ABVC 0.15
- MACD
- CELU -0.02
- ABVC -0.01
- Stochastic Oscillator
- CELU 21.15
- ABVC 32.79
About CELU Celularity Inc.
Celularity Inc is a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies including genetically modified and unmodified NK cells, engineered T cells including CAR-T cells, and mesenchymal-like adherent stromal cells, targeting indications across cancer, immunologic, infectious, and degenerative diseases. It manages its operations through an evaluation of three distinct business segments which include Cell Therapy, Degenerative Disease, and bio-banking. The company generates the majority of its revenue from the bio-banking segment.
About ABVC ABVC BioPharma Inc.
ABVC BioPharma Inc is a clinical-stage biopharmaceuticals company with an active pipeline of six drugs and one medical device (ABV-1701/Vitargus) under development. Its drug products focus on utilizing its licensed technology to conduct proof-of-concept trials through Phase II of the clinical development process. The firm specializes in botanically based solutions that deliver high efficacy with low toxicity for improved health outcomes.